On October 8, 2024, "Taimi Medical," an investee company of Beartree Capital, a sub-fund backed by the fund managed by Yuanhe Chencun, was listed on the Main Board of the Hong Kong Stock Exchange, with stock code: 02576.HK.

As a digital solutions provider specializing in the pharmaceutical and medical device industries, Taimei Medical Technology has been dedicated since its establishment in 2013 to leveraging cutting-edge digital and intelligent technologies to drive growth in these sectors—and ultimately improve healthcare outcomes for patients worldwide. To address the challenges of industry collaboration, the company has innovatively developed two pioneering digital collaboration platforms: TrialOS and PharmaOS. These platforms seamlessly connect hospitals, pharmaceutical companies, third-party service providers, patients, and regulatory agencies, fostering standardized data exchange, streamlined workflows, and integrated resource management. By doing so, Taimei is helping the industry accelerate its digital and intelligent transformation, boosting overall R&D efficiency in pharmaceuticals and medical devices, enhancing post-launch commercial performance, and enabling win-win value creation across all stakeholders.

Taimei Medical is a national-level "Little Giant" enterprise specializing in niche expertise and innovation, as well as a National High-Tech Enterprise. As of March 31, 2024, Taimei Medical Technology has served more than 1,400 pharmaceutical companies and CROs, including 21 of the world’s top 25 pharmaceutical giants and 90 of China’s Top 100 Innovative Pharmaceutical Companies. The company has also established partnerships with over 700 national drug clinical trial institutions, with more than 80% of these being Grade III Class A hospitals. By customer count, Taimei has become the most widely adopted digital solution provider in China’s pharmaceutical and medical device R&D and marketing sectors.